ImmuneOncia Therapeutics Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	111.21	654.54	110	7,733	35.95
Other Revenue	-	-	-	-	0
Revenue	111.21	654.54	110	7,733	35.95
Revenue Growth (YoY)	-83.01%	495.04%	-98.58%	21413.29%	1337.90%
Cost of Revenue	12.95	11.12	17.09	17.85	7.8
Gross Profit	98.26	643.42	92.91	7,716	28.15
Selling, General & Admin	7,439	4,964	5,038	7,662	5,075
Research & Development	19,821	7,386	6,034	14,243	6,012
Amortization of Goodwill & Intangibles	575.73	574.44	565.53	567.15	567.03
Other Operating Expenses	35.77	19.64	19.55	15.15	12.63
Operating Expenses	28,103	13,242	11,890	22,789	11,924
Operating Income	-28,005	-12,599	-11,797	-15,073	-11,896
Interest Expense	-5.12	-6.93	-3.13	-	-
Interest & Investment Income	706.03	690.31	769.15	-	-
Currency Exchange Gain (Loss)	-41.66	-49.41	9.51	75.7	192.43
Other Non Operating Income (Expenses)	-17.66	6,278	19,886	11,507	-48,783
EBT Excluding Unusual Items	-27,363	-5,686	8,865	-3,490	-60,487
Gain (Loss) on Sale of Assets	-	-0.55	-0.77	-1.38	-3.18
Pretax Income	-27,363	-5,687	8,864	-3,492	-60,490
Net Income	-27,363	-5,687	8,864	-3,492	-60,490
Net Income to Common	-27,363	-5,687	8,864	-3,492	-60,490
Shares Outstanding (Basic)	70	56	52	52	46
Shares Outstanding (Diluted)	70	56	52	52	46
Shares Change (YoY)	24.61%	7.35%	0.64%	12.17%	904.47%
EPS (Basic)	-390.00	-101.00	169.00	-67.00	-1302.00
EPS (Diluted)	-390.00	-101.00	169.00	-67.00	-1302.00
Free Cash Flow	-23,105	-14,757	-8,766	-15,337	-2,078
Free Cash Flow Per Share	-329.32	-262.08	-167.13	-294.29	-44.72
Gross Margin	88.36%	98.30%	84.47%	99.77%	78.31%
Operating Margin	-25182.04%	-1924.80%	-10724.51%	-194.91%	-33093.66%
Profit Margin	-24605.12%	-868.86%	8058.20%	-45.15%	-168272.99%
Free Cash Flow Margin	-20776.54%	-2254.59%	-7968.93%	-198.32%	-5779.96%
EBITDA	-27,114	-11,547	-10,766	-13,992	-10,870
EBITDA Margin	-	-	-	-180.93%	-
D&A For EBITDA	890.41	1,051	1,031	1,081	1,026
EBIT	-28,005	-12,599	-11,797	-15,073	-11,896
EBIT Margin	-	-	-	-194.91%	-
Advertising Expenses	2.08	1	1	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.